Your browser doesn't support javascript.
loading
SRGN-Triggered Aggressive and Immunosuppressive Phenotype in a Subset of TTF-1-Negative Lung Adenocarcinomas.
Tanaka, Ichidai; Dayde, Delphine; Tai, Mei Chee; Mori, Haruki; Solis, Luisa M; Tripathi, Satyendra C; Fahrmann, Johannes F; Unver, Nese; Parhy, Gargy; Jain, Rekha; Parra, Edwin R; Murakami, Yoshiko; Aguilar-Bonavides, Clemente; Mino, Barbara; Celiktas, Muge; Dhillon, Dilsher; Casabar, Julian Phillip; Nakatochi, Masahiro; Stingo, Francesco; Baladandayuthapani, Veera; Wang, Hong; Katayama, Hiroyuki; Dennison, Jennifer B; Lorenzi, Philip L; Do, Kim-Anh; Fujimoto, Junya; Behrens, Carmen; Ostrin, Edwin J; Rodriguez-Canales, Jaime; Hase, Tetsunari; Fukui, Takayuki; Kajino, Taisuke; Kato, Seiichi; Yatabe, Yasushi; Hosoda, Waki; Kawaguchi, Koji; Yokoi, Kohei; Chen-Yoshikawa, Toyofumi F; Hasegawa, Yoshinori; Gazdar, Adi F; Wistuba, Ignacio I; Hanash, Samir; Taguchi, Ayumu.
Afiliação
  • Tanaka I; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Dayde D; Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.
  • Tai MC; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Mori H; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Solis LM; Division of Molecular Diagnostics, Aichi Cancer Center, Nagoya, Japan.
  • Tripathi SC; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Fahrmann JF; Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Unver N; Department of Biochemistry, All India Institute of Medical Sciences, Nagpur, Maharashtra, India.
  • Parhy G; Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Jain R; Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Parra ER; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Murakami Y; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Aguilar-Bonavides C; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Mino B; Department of Pathology and Molecular Diagnostics, Aichi Cancer Center Hospital, Nagoya, Japan.
  • Celiktas M; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Dhillon D; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Casabar JP; Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Nakatochi M; Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Stingo F; Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Baladandayuthapani V; Public Health Informatics Unit, Department of Integrated Health Sciences, Nagoya University Graduate School of Medicine, Nagoya, Japan.
  • Wang H; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Katayama H; Department of Statistica, Informatica, Applicazioni "G. Parenti", University of Florence, Florence, Italy.
  • Dennison JB; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Lorenzi PL; Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Do KA; Hangzhou Cosmos Wisdom Mass Spectrometry Center of Zhejiang University Medical School, Xiaoshan District, Hangzhou, Zhejiang, China.
  • Fujimoto J; Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Behrens C; Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Ostrin EJ; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Rodriguez-Canales J; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Hase T; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Fukui T; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Kajino T; Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Kato S; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Yatabe Y; Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.
  • Hosoda W; Department of Thoracic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.
  • Kawaguchi K; Division of Molecular Diagnostics, Aichi Cancer Center, Nagoya, Japan.
  • Yokoi K; Department of Pathology and Molecular Diagnostics, Aichi Cancer Center Hospital, Nagoya, Japan.
  • Chen-Yoshikawa TF; Department of Pathology and Molecular Diagnostics, Aichi Cancer Center Hospital, Nagoya, Japan.
  • Hasegawa Y; Department of Pathology and Molecular Diagnostics, Aichi Cancer Center Hospital, Nagoya, Japan.
  • Gazdar AF; Department of Thoracic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.
  • Wistuba II; Department of Thoracic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.
  • Hanash S; Department of Thoracic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.
  • Taguchi A; Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.
J Natl Cancer Inst ; 114(2): 290-301, 2022 02 07.
Article em En | MEDLINE | ID: mdl-34524427
ABSTRACT

BACKGROUND:

Approximately 20% of lung adenocarcinoma (LUAD) is negative for the lineage-specific oncogene Thyroid transcription factor 1 (TTF-1) and exhibits worse clinical outcome with a low frequency of actionable genomic alterations. To identify molecular features associated with TTF-1-negative LUAD, we compared the transcriptomic and proteomic profiles of LUAD cell lines. SRGN , a chondroitin sulfate proteoglycan Serglycin, was identified as a markedly overexpressed gene in TTF-1-negative LUAD. We therefore investigated the roles and regulation of SRGN in TTF-1-negative LUAD.

METHODS:

Proteomic and metabolomic analyses of 41 LUAD cell lines were done using mass spectrometry. The function of SRGN was investigated in 3 TTF-1-negative and 4 TTF-1-positive LUAD cell lines and in a syngeneic mouse model (n = 5 to 8 mice per group). Expression of SRGN was evaluated in 94 and 105 surgically resected LUAD tumor specimens using immunohistochemistry. All statistical tests were 2-sided.

RESULTS:

SRGN was markedly overexpressed at mRNA and protein levels in TTF-1-negative LUAD cell lines (P < .001 for both mRNA and protein levels). Expression of SRGN in LUAD tumor tissue was associated with poor outcome (hazard ratio = 4.22, 95% confidence interval = 1.12 to 15.86, likelihood ratio test, P = .03), and with higher expression of Programmed cell death 1 ligand 1 (PD-L1) in tumor cells and higher infiltration of Programmed cell death protein 1-positive lymphocytes. SRGN regulated expression of PD-L1 as well as proinflammatory cytokines, including Interleukin-6, Interleukin-8, and C-X-C motif chemokine 1 in LUAD cell lines; increased migratory and invasive properties of LUAD cells and fibroblasts; and enhanced angiogenesis. SRGN was induced by DNA demethylation resulting from Nicotinamide N-methyltransferase-mediated impairment of methionine metabolism.

CONCLUSIONS:

Our findings suggest that SRGN plays a pivotal role in tumor-stromal interaction and reprogramming into an aggressive and immunosuppressive tumor microenvironment in TTF-1-negative LUAD.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Proteoglicanas / Fatores de Transcrição / Proteínas de Transporte Vesicular / Proteínas de Ligação a DNA / Adenocarcinoma de Pulmão / Neoplasias Pulmonares Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Proteoglicanas / Fatores de Transcrição / Proteínas de Transporte Vesicular / Proteínas de Ligação a DNA / Adenocarcinoma de Pulmão / Neoplasias Pulmonares Idioma: En Ano de publicação: 2022 Tipo de documento: Article